Why Pharma Is Rethinking the Centralized Hub Model

Key Takeaways

• Centralized hubs struggle with complex specialty therapy demands.
• “Hubless hub” distributes prior‑auth, financial aid, analytics across tech partners.
• Automation raises net prior‑auth approval rates, cuts resolution time.
• Access teams now align with commercial strategy for earlier barrier mitigation.
• McKesson’s exit signals industry-wide shift toward modular access solutions.

Pulse Analysis

The traditional centralized hub emerged when payers, providers, and manufacturers operated in silos, making a single call‑center the most efficient way to manage benefits investigations and prior‑authorizations. Over time, that model proved cumbersome as specialty drugs grew in cost and therapeutic complexity, and payer criteria became increasingly dynamic. Companies found that scaling a monolithic hub could not keep pace with the speed required for modern patient journeys, prompting a reevaluation of how access services are delivered.

Enter the "hubless hub," a modular ecosystem that layers automation, real‑time payer intelligence, and digital enrollment tools directly into the point‑of‑care workflow. Prior‑authorization tasks are now handled by AI‑driven platforms that pull eligibility data instantly, while financial assistance programs are offered through patient‑support apps that streamline co‑pay enrollment. Analytics dashboards give manufacturers visibility into approval rates, turnaround times, and bottlenecks, enabling rapid course corrections. Early benchmarks from SamaCare show net approval rates hovering around 80% and resolution times shrinking to two days for many payers, a marked improvement over the week‑long cycles typical of legacy hubs.

Strategically, the distributed model blurs the line between market access and commercial functions. Access teams collaborate earlier with brand managers to anticipate coding challenges, step‑therapy requirements, and site‑of‑care shifts such as the rise of infusion centers. This integrated approach not only accelerates patient treatment initiation but also safeguards revenue forecasts by reducing denial‑related gaps. As more pharma firms adopt modular platforms, the industry is likely to see a wave of partnerships with technology vendors, heightened data transparency, and a new standard for measuring access performance that ties directly to commercial outcomes.